These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 11744594)
1. Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients. Ferring M; Reber G; de Moerloose P; Merlani P; Diby M; Ricou B Can J Anaesth; 2001 Dec; 48(11):1155-60. PubMed ID: 11744594 [TBL] [Abstract][Full Text] [Related]
2. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066 [TBL] [Abstract][Full Text] [Related]
3. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Toulon P; Ozier Y; Ankri A; Fléron MH; Leroux G; Samama CM Thromb Haemost; 2009 Feb; 101(2):394-401. PubMed ID: 19190827 [TBL] [Abstract][Full Text] [Related]
4. Use of the activated partial thromboplastin time for heparin monitoring. Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801 [TBL] [Abstract][Full Text] [Related]
5. The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients. Karigowda L; Deshpande K; Jones S; Miller J Pathology; 2019 Oct; 51(6):628-633. PubMed ID: 31445807 [TBL] [Abstract][Full Text] [Related]
6. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants. Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin. Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J Angiology; 2009; 60(3):358-61. PubMed ID: 19398428 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a point-of-care coagulation analyzer on patients undergoing cardiopulmonary bypass surgery. Chavez JJ; Weatherall JS; Strevels SM; Liu F; Snider CC; Carroll RC J Clin Anesth; 2004 Feb; 16(1):7-10. PubMed ID: 14984853 [TBL] [Abstract][Full Text] [Related]
12. Point-of-care (POC) measurement of coagulation after cardiac surgery. Boldt J; Walz G; Triem J; Suttner S; Kumle B Intensive Care Med; 1998 Nov; 24(11):1187-93. PubMed ID: 9876982 [TBL] [Abstract][Full Text] [Related]
13. Central venous catheter sampling of low molecular heparin levels: an approach to increasing result reliability. Bauman ME; Belletrutti M; Bauman ML; Massicotte MP Pediatr Crit Care Med; 2012 Jan; 13(1):1-5. PubMed ID: 21317677 [TBL] [Abstract][Full Text] [Related]
14. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Dempfle CE; Lorenz S; Smolinski M; Wurst M; West S; Houdijk WP; Quintel M; Borggrefe M Crit Care Med; 2004 Feb; 32(2):520-4. PubMed ID: 14758173 [TBL] [Abstract][Full Text] [Related]
15. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785 [TBL] [Abstract][Full Text] [Related]
16. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794 [TBL] [Abstract][Full Text] [Related]
17. Point-of-care versus central laboratory testing: an economic analysis in an academic medical center. Tsai WW; Nash DB; Seamonds B; Weir GJ Clin Ther; 1994; 16(5):898-910; discussion 854. PubMed ID: 7859247 [TBL] [Abstract][Full Text] [Related]
19. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy. Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710 [TBL] [Abstract][Full Text] [Related]
20. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Ip BK; Thomson AR; Moriarty HT Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]